Despite the challenges of the pandemic, the healthcare provider experienced strong operational and financial performance in the third quarter. Same store net revenue increased 7.1% year over year, driven by a 2.8% increase in admissions and a 24.2% increase in ER visits. Adjusted EBITDA grew 7% to $463 million, with an adjusted EBITDA margin of 14.8%. The surge in COVID-19 cases resulted in higher costs for staffing, pharmaceuticals, and supplies, but the company effectively managed expenses and maintained its dual-track operation strategy. The company has invested heavily in growth initiatives such as new bed capacity, outpatient access points, and physician recruitment, which have improved its competitive position and market share. Amidst the challenging environment, the company raised its adjusted EBITDA guidance to $1.780 billion to $1.820 billion for the full year, reflecting its optimism about its portfolio, markets, and long-term growth potential.